Evolving Paradigm of PARP-Inhibitors and Combination Therapies for mCRPC – Enduring Webcast

Description

Program Description

---

There is an unmet need to develop newer therapies beyond targeting AR signaling for mCRPC. PARP inhibitors are targeted agents that treat HRR-deficient tumors. Olaparib, rucaparib, niraparib, veliparib, and talazoparib were evaluated in phase trials as monotherapy and with combinations for mCRPC. The combination approach has shown impressive early efficacy signals in clinical settings and appears poised for a breakthrough.

Intended Audience

---

This webcast is designed to meet the educational needs of medical oncologists, urologists, physician assistants, and nurse practitioners.

Commercial Supporter

---

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen.